Vertex Pharmaceuticals Shares Sold by Schroder Investment Management

Institutional investor trims stake in biotech firm focused on cystic fibrosis treatments

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Schroder Investment Management Group reduced its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.9% in the third quarter, according to the company's recent SEC filing. Schroder Investment Management Group now owns 121,587 shares of the pharmaceutical company's stock worth $48,065,000.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm known for its innovative treatments for cystic fibrosis, a genetic disorder that affects the lungs and digestive system. The company's CFTR modulators have transformed standards of care for many CF patients. Institutional investors closely watch Vertex's performance as it is considered a bellwether for the broader biotech sector.

The details

Schroder Investment Management Group trimmed its stake in Vertex Pharmaceuticals by selling 13,380 shares during the third quarter. The firm now owns 121,587 shares of the pharmaceutical company's stock worth $48,065,000. Several other large investors have also recently added to or reduced their positions in Vertex Pharmaceuticals.

  • Schroder Investment Management Group reduced its holdings in Vertex Pharmaceuticals in the third quarter of 2026.

The players

Schroder Investment Management Group

A global asset management firm that has reduced its stake in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing treatments for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Vertex Pharmaceuticals' innovative cystic fibrosis treatments have made it a closely watched company in the biotech sector. The reduction in Schroder Investment Management Group's stake suggests institutional investors are closely monitoring the company's performance and positioning within the industry.